Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The Indian government has withdrawn Quality Control Orders (QCOs) for critical materials like polypropylene and polycarbonate following an industry / NITI Aayog review, easing sourcing complexity for domestic medical-device manufacturers.
Source: h7.cl/1jJYy

2. The Supreme Court has requested the Centre and states to create a unified national policy under the Transplantation of Human Organs Act, citing stark inconsistencies across states in donor criteria, allocation norms and regulation. It also called for donor-welfare guidelines, uniform registry formats, brain-death reporting and swift establishment of organ-tissue organisations in lagging regions.
Source: h7.cl/1eVn7

3. India’s Union Commerce Ministry has sought detailed industry inputs on market access barriers for pharmaceutical exports to Russia, focusing on registration, market entry, price rules, and clinical trials, as it prepares submissions for upcoming talks in Moscow to strengthen India’s expanding pharmaceutical presence across Russia and the wider Eurasian region.
Source: h7.cl/1eVnb

4. The Indian government is reportedly considering tighter regulation of health insurance to curb soaring premiums, driven by rising medical costs and uneven claim payouts. Proposed measures include capping premiums, limiting agent commissions, and requiring stricter disclosure norms. Discussions are ongoing with the IRDAI, insurers, and hospitals to evaluate the measures.
Source: h7.cl/1eVnf

5. India’s leading food delivery platform is reportedly close to an agreement with restaurant associations to share customer contact details and ordering insights, subject to user consent. The move aims to resolve long-standing disputes over data access and could set a new industrywide model for platform restaurant data sharing.
Source: h7.cl/1jJZC

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Reader, We are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

Panel of auditors to audit the promotional expenses of pharma and medical device companies will be appointed soon: Government
The Secretary, Department of Pharmaceuticals, has reportedly said that the government will appoint a panel of auditors who can undertake risk-based audits from time to time, to evaluate whether the promotional expenses, especially towards conferences and workshops, have been incurred in an ethical manner as per the Uniform Code for Pharmaceutical Marketing Practices 2024. Any discrepancy will be reported to the appropriate government agency or authority.
Source: bit.ly/49SNs5f

Industry welcomes the new Uniform Code for Pharmaceutical Marketing Practices
The pharmaceutical industry has reportedly welcomed the new Uniform Code for Pharmaceutical Marketing Practices (UCPMP). According to news reports, the industry feels that the new code is a step ahead towards the advancement of the industry as it ensures ethical and healthy engagement between the pharmaceutical industry and medical professionals.
Source: bit.ly/4a6SZWd

Nutraceutical and food supplement regulations are to be tightened further
The Food Safety and Standards Authority of India (FSSAI) is in the process of tightening the regulations for nutraceuticals and health supplements. This move was prompted by the receipt of several complaints by the FSSAI about the presence of non-compliant health supplements on the market and the fact that the over-the-counter availability of nutraceuticals and health supplements is resulting in people consuming supplements along with drugs, which increases the risk of adverse effects.
Source: bit.ly/3wXMsOU

A major e-commerce entity was fined Rs 25 lakh due to its inaction to remove counterfeit products from the marketplace
A State Consumer Commission in India has imposed a fine of Rs. 25 lakhs on a major e-commerce entity on the grounds that the e-commerce entity failed to correct the listing of a product, which it was aware was a counterfeit product. By failing to remove the listing, the Commission held that the e-commerce entity had engaged in dark patterns and unjust enrichment.
Source: bit.ly/3IBUsaH

EU to extend regulatory data protection for innovator drugs to 7.5 years
The European Union is set to extend regulatory data protection for innovator drugs to 7.5 years, with one extra year of incentives if the drug meets an unmet medical need and clinical trials are conducted in the EU. There is a proposal to grant an additional 3 years of protection from generics, taking the total protection to a maximum of 11.5 years.
Source: bit.ly/3IxEIWl